We have approximately 500 employees in the company. Fosun Long March has been rewarded with prizes by Ministry of Health, Shanghai Science and Technical Committee and Industry Associations. Also Fosun Long March has been recognized as `High-Tech Enterprise` by Shanghai Government.

As the investment platform of IVD division of FosunPharma Group, Fosun Long March has speeded up merger and acquisition in the centre of new product introduction. We directly hold Yaneng Biosciences (Shenzhen) Co., Ltd, Shanghai Fosun Med-Tech Development Co., Shanghai Biofosun Biotech Co., Ltd and Jiangsu Star Diagnostics Co.,Ltd. We partly hold SINNOWA Medical Science & Technology Co., LTD and Steellex Scientific Instrument Company. At the same time, we also have close cooperation with Saladax USA, and SDB Korea through FosunPharma.

Currently the company has obtained CFDA approval for a hundred products, and more than ten patents. The imported product T-spot TB, as only authorized Sitemap tuberculosis diagnosis kits in China market, filled the gaps in this field for domestic market.

Fosun Long March strives to be the leading provider of in-vitro diagnostics solutions in China. We will continue our research and development, introduction of advanced technology and cooperation with research institute in future.

Model GUC-1 - Multifunction Monitoring System